Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
Edward Keystone(Mount Sinai Hospital), Mahboob U. Rahman(University of Pennsylvania), Zhixian Wu(Bureau of Geology and Mineral Exploration and Development of Guizhou Province), Stephen Hall(Cabrini Hospital), J Pazdur, Pedro C. Miranda(Hospital Universitario de La Princesa), Maria Wiekowski, Sudha Visvanathan, Lars Klareskog(Karolinska University Hospital), E. C. Hsia(University of Pennsylvania), Mark C. Genovese(Stanford University), Julie Zrubek, William Palmer
Cited by 540
Related Papers
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
|The Lancet|2004|1.8k
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
|Pharmacology & Therapeutics|2007|1.6k
A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination
|Arthritis & Rheumatism|2005|1.5k
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
|New England Journal of Medicine|2005|1.2k